<DOC>
	<DOCNO>NCT02411994</DOCNO>
	<brief_summary>The purpose study determine efficacy pyronaridine-artesunate artemether-lumefantrine treatment uncomplicated Plasmodium falciparum malaria Kenyan child .</brief_summary>
	<brief_title>Pyronaridine-artesunate Artemether-lumefantrine Treatment Paediatric Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>Children 6 month 12 year old , body weight ≥5 kg ; Living catchment area study ( within radius ~10 km St. Jude 's Clinic , Mbita , Kenya ) ; Having microscopically confirm P. falciparum monoinfection ( asexual parasite density 1,000200,000 µL1 ) . Signs symptom severe malaria ( accord WHO criteria severe malaria , ( WHO 2012 ) ) severe illness necessitate parenteral treatment ; Mixed Plasmodium infection ; Clinically suspect ( oedema , jaundice and/or ascites ) report hepatic and/or renal impairment ( cause , report parents/guardians and/or evident medical history ) ; Having anaemia Hb &lt; 6 g/dL ; Evidence severe malnutrition ( severe wasting : zscore weight age &lt; 3 severe stunting : zscore height age &lt; 3 ( WHO 2009b ) ) ; Having receive antimalarial therapy previous two week ; Known history hypersensitivity , allergic adverse reaction artesunate , artemetherlumefantrine artemisinins ; Participating antimalarial drug intervention study ; Previous participation PAAL study , e.g . previous transmission season ( individual child take part study ) ; Not available followup .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>